$5.37−0.12 (−2.19%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Kazia Therapeutics (KZIA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 65% below its peak, net margin −4736.1%.
The lines that matter · FY22–FY26
Revenue ($K)▼51.5%
583.6
FY23→FY26CAGR +236.4%/yr
Net income ($K)▼103.1%
−27,641.3
FY22→FY26CAGR —
Diluted EPS▲70.2%
−0.01
FY22→FY26CAGR —
What the receipts whisper · what a headline number hides
Share count
+0.0%
6.3bn → 6.3bn diluted shares since FY26. Broadly flat, so EPS moves with net income rather than with the share count.
What the income statement says · FY22–FY26
Where every revenue dollar goes · FY26 ($K)
-4736¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 100.0% → 100.0%. Net margin -4736.1% is below the sector median.
The receipt · income statement · FY22–FY26 USD thousands except per-share & ratios · hover a line for its definition
On the latest annual statement the reported earnings per share does not reconcile with net income to common shareholders divided by the reported share count (a factor of 1.589), so the two figures are on different bases. Both are shown as filed.
USD thousands except per-share & ratios
| Line item | FY26 | FY25 | FY24 | FY23 | FY22 | YoY | CAGR 22→26 |
|---|---|---|---|---|---|---|---|
| Revenue & profitability | |||||||
Revenue | 583.6 | 1,202.2 | 1,656.6 | 15.3 | −69.0 | ▼51.5% | +236.4% (23→26) |
Cost of revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 583.6 | 1,202.2 | 1,656.6 | 15.3 | −69.0 | ▼51.5% | +236.4% (23→26) |
Research & development | 7,329.2 | 4,815.4 | 11,604.6 | 10,370.3 | 13,926.7 | ▲52.2% | −14.8% |
Selling, general & admin | 14,374.2 | 5,731.7 | 9,056.0 | 5,718.9 | 3,530.5 | ▲150.8% | +42.0% |
Total operating expenses | 21,703.4 | 14,375.8 | 20,581.2 | 13,831.7 | 17,457.2 | ▲51.0% | +5.6% |
Operating incomefeeds ROC rank | −21,119.8 | −13,173.6 | −18,924.6 | −13,816.4 | −17,526.3 | ▼60.3% | — |
Other income, net | −6,521.5 | −1,581.5 | 864.0 | 0.0 | 0.0 | — | — |
Pretax income | −27,641.3 | −14,755.1 | −18,060.6 | −13,816.4 | −17,526.3 | ▼87.3% | — |
Income tax | 0.0 | −1,147.6 | −180.9 | −180.6 | −254.1 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −27,641.3 | −13,607.4 | −17,879.7 | −13,635.8 | −17,272.2 | ▼103.1% | — |
| Per share | |||||||
Diluted EPSbuyback-sensitive | −0.01 | −0.02 | −0.07 | −0.07 | −0.13 | — | — |
Diluted shares (bn) | 6.35 | 0.81 | 0.33 | 0.23 | 0.14 | ▲684.1% | +160.1% |
| Margins | |||||||
Gross margin80th pct in Healthcare | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ▲0.0pp | +0.0pp |
Operating margin | −3618.7% | −1095.8% | −1142.4% | −90155.9% | 25382.0% | ▼2522.9pp | −29000.7pp |
Net margin4th pct in Healthcare | −4736.1% | −1131.9% | −1079.3% | −88977.7% | 25014.0% | ▼3604.3pp | −29750.1pp |
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-11-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Kazia Therapeutics' revenue last fiscal year?
Kazia Therapeutics reported revenue of $583.6K in fiscal 2026, down 51.5% from fiscal 2025.
What was Kazia Therapeutics' net income?
Kazia Therapeutics reported net income of −$27,641.3K in fiscal 2026, a net margin of −4736.1%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

